Mirabegron + Solifenacin succinate + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Urologic Diseases
Conditions
Urologic Diseases, Urinary Bladder Diseases, Urological Manifestations, Signs and Symptoms, Urinary Bladder, Overactive
Trial Timeline
Mar 29, 2011 → Jun 28, 2012
NCT ID
NCT01340027About Mirabegron + Solifenacin succinate + Placebo
Mirabegron + Solifenacin succinate + Placebo is a phase 2 stage product being developed by Astellas Pharma for Urologic Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT01340027. Target conditions include Urologic Diseases, Urinary Bladder Diseases, Urological Manifestations.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01340027 | Phase 2 | Completed |
Competing Products
16 competing products in Urologic Diseases
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| pemetrexed + cisplatin | Eli Lilly | Phase 1/2 | 41 |
| Mirabegron + Solifenacin succinate | Astellas Pharma | Phase 3 | 77 |
| Gemcitabine | Eli Lilly | Phase 2 | 52 |
| pemetrexed | Eli Lilly | Phase 2 | 52 |
| ALIMTA + gemcitabine | Eli Lilly | Phase 2 | 52 |
| BBI503 | Sumitomo Pharma | Phase 2 | 52 |
| Pembrolizumab Injection [Keytruda] | Merck | Phase 2 | 52 |
| Carboplatin/Paclitaxel + Pembrolizumab | Merck | Phase 2 | 52 |
| zoledronic acid | Novartis | Phase 2 | 52 |
| mycophenolate mofetil | Roche | Phase 1 | 33 |
| Cetuximab + Paclitaxel | Bristol Myers Squibb | Phase 2 | 51 |
| Nivolumab + Relatlimab | Bristol Myers Squibb | Phase 2 | 51 |
| CBT101 + Placebo | Brain Biotech | Phase 1 | 25 |
| OGX-427 600 mg + OGX-427 1000 mg + Placebo + Gemcitabine + Cisplatin + Carboplatin | Achieve Life Sciences | Phase 2 | 44 |
| S-8184 Paclitaxel Injectable Emulsion + Experimental Arm: TOCOSOL Paclitaxel | Achieve Life Sciences | Phase 2 | 44 |
| Stem Cell | Brain Biotech | Phase 1 | 25 |